Results 81 to 90 of about 18,115 (178)
, 2018 En este informe de la European Network for Health Technology Assessment (EUnetHTA), se evalúa la eficacia y seguridad de regorafenib en el tratamiento de pacientes adultos con carcinoma hepatocelular que han sido tratados previamente con sorafenib. AETSA
core
Pharmacology Research & Perspectives, 2019 Age‐related macular degeneration (AMD) is the leading cause of severe vision impairment in patients over the age of 60 years. Choroidal neovascularization (CNV) is the hallmark of neovascular AMD and vascular endothelial growth factor (VEGF) plays a ...
Shinya Horita +6 more
doaj +1 more source
Therapeutic Advances in Medical Oncology, 2020 Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is a novel oral multikinase inhibitor that blocks the activity of several protein kinases. However, few guidelines exist for novel biomarkers to select patients who will likely benefit
Min-Sang Lee +10 more
doaj +1 more source
Journal of Surgical Oncology, Volume 134, Issue 4, Page 490-501, September 15, 2026.ABSTRACT Sarcomas represent a diverse group of mesenchymal tumors with high rates of recurrence after resection. While recent technical advances have enabled the detection of rare circulating tumor DNA (ctDNA) in other malignancies, the complexity and heterogeneity of sarcoma genomics have historically limited ctDNA in these cancers.
Kristin E. Goodsell +5 more
wiley +1 more source
, 2016 Jörg Trojan, Oliver Waidmann Medizinische Klinik 1, Universitätsklinikum Frankfurt, Germany Abstract: Sorafenib is still the only systemic drug approved for the treatment of advanced hepatocellular carcinoma (HCC).
Waidmann O, Trojan J
core
REGORAFENIB IN GLIOBLASTOMA: in vitro CHARACTERIZATION OF TUMOR CELLS RESPONSE
, 2023 Glioblastoma IDH wild-type (GBM), is the most malignant primary brain tumor in adults. A phase II clinical trial (REGOMA)1 demonstrated that the multikinase inhibitor regorafenib significantly increased the median overall survival of GBM patients when ...
Maria Patrizia Mongiardi +6 more
core
High‐Content CRISPR Screening: Methods and Applications
MedComm, Volume 7, Issue 9, September 2026.High‐content CRISPR screening represents a paradigm shift in functional genomics, moving beyond traditional survival‐based readouts to enable multidimensional mapping of genotype–phenotype relationships. This review systematically outlines the methodological evolution of this approach, detailing advances in perturbation modalities, delivery systems ...
Yike Zhang +6 more
wiley +1 more source
Regorafenib in metastatic colorectal cancer
, 2014 Regorafenib is an oral multikinase inhibitor that blocks the activity of protein kinases involved in the regulation of tumor angiogenesis (VEGFR1, 2, 3; angiopoietin-1 receptor), oncogenesis (stem cell growth factor receptor; RET; BRAF including ...
R. Ricotta +5 more
core +1 more source
The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenografts [PDF]
, 2022 The multi-kinase inhibitor Regorafenib, approved for the treatment of metastatic colorectal cancer, is poorly tolerated with a Grade 3/4 drug related adverse event rate of 54% resulting in frequent dose reductions and discontinuations.
Oronsky, Bryan +4 more
core
Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 532-544, September 2026.ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson +5 more
wiley +1 more source